These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
3. Challenges and solutions to pre- and post-randomization subgroup analyses. Desai M; Pieper KS; Mahaffey K Curr Cardiol Rep; 2014; 16(10):531. PubMed ID: 25135344 [TBL] [Abstract][Full Text] [Related]
4. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102 [TBL] [Abstract][Full Text] [Related]
5. Primer: the fallacy of subgroup analysis. Guillemin F Nat Clin Pract Rheumatol; 2007 Jul; 3(7):407-13. PubMed ID: 17599075 [TBL] [Abstract][Full Text] [Related]
6. Level of evidence for promising subgroup findings: The case of trends and multiple subgroups. Tanniou J; Smid SC; van der Tweel I; Teerenstra S; Roes KCB Stat Med; 2019 Jun; 38(14):2561-2572. PubMed ID: 30868624 [TBL] [Abstract][Full Text] [Related]
7. Issues related to subgroup analysis in clinical trials. Cui L; Hung HM; Wang SJ; Tsong Y J Biopharm Stat; 2002 Aug; 12(3):347-58. PubMed ID: 12448576 [TBL] [Abstract][Full Text] [Related]
8. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. Hayward RA; Kent DM; Vijan S; Hofer TP BMC Med Res Methodol; 2006 Apr; 6():18. PubMed ID: 16613605 [TBL] [Abstract][Full Text] [Related]
9. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J; Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365 [TBL] [Abstract][Full Text] [Related]
10. Hypothesis testing in clinical trials. Green SB Hematol Oncol Clin North Am; 2000 Aug; 14(4):785-95, vii-viii. PubMed ID: 10949773 [TBL] [Abstract][Full Text] [Related]
11. Interaction effects and subgroup analyses in clinical trials: more than meets the eye? Sevdalis N; Jacklin R J Eval Clin Pract; 2008 Oct; 14(5):919-22. PubMed ID: 18373582 [TBL] [Abstract][Full Text] [Related]
12. Inference on subgroups identified based on a heterogeneous treatment effect in a post hoc analysis of a clinical trial. Zhao B; Ivanova A; Fine J Clin Trials; 2023 Aug; 20(4):370-379. PubMed ID: 37170632 [TBL] [Abstract][Full Text] [Related]
13. Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes. Tanniou J; van der Tweel I; Teerenstra S; Roes KC BMC Med Res Methodol; 2016 Feb; 16():20. PubMed ID: 26891992 [TBL] [Abstract][Full Text] [Related]
14. Statistical properties of randomization in clinical trials. Lachin JM Control Clin Trials; 1988 Dec; 9(4):289-311. PubMed ID: 3060315 [TBL] [Abstract][Full Text] [Related]
15. Post hoc subgroup analysis and the truth of a clinical trial. Adams KF Am Heart J; 1998 Nov; 136(5):753-8. PubMed ID: 9812066 [No Abstract] [Full Text] [Related]
16. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials. Dmitrienko A; Muysers C; Fritsch A; Lipkovich I J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479 [TBL] [Abstract][Full Text] [Related]
17. A flexible strategy for testing subgroups and overall population. Alosh M; Huque MF Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704 [TBL] [Abstract][Full Text] [Related]
18. Post hoc analyses: after the facts. Srinivas TR; Ho B; Kang J; Kaplan B Transplantation; 2015 Jan; 99(1):17-20. PubMed ID: 25525920 [TBL] [Abstract][Full Text] [Related]